Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Century Therapeutics, Inc. (IPSC : NSDQ)

• Company Description    Century Therapeutics Inc. is a cell therapy company. It involved in developing induced pluripotent stem cell -derived cell therapies in immuno-oncology. Century Therapeutics Inc. is based in PHILADELPHIA. Number of Employees: 78

• Price / Volume Information    Yesterday's Closing Price: $2.26 Daily Weekly Monthly 20 Day Moving Average: 673,697 shares Shares Outstanding: 180.35 (millions) Market Capitalization: $407.60 (millions) Beta: 1.55 52 Week High: $3.04 52 Week Low: $0.44 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 0.00% -4.88% 12 Week 0.89% -6.73% Year To Date 127.18% 109.79%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 25 N 38 th Street 11th Floor - PHILADELPHIA,PA 19104 USA ph: 267-817-5790 fax: - investor.relations@centurytx.com http://www.centurytx.com

• General Corporate Information    Officers Brent Pfeiffenberger - Chief Executive Officer and Chairman Douglas Carr - Senior Vice President; Finance & Operations Kimberly Blackwell - Director Han Lee - Director Martin Murphy - Director Peer Information Century Therapeutics, Inc. (GSAC) Century Therapeutics, Inc. (CASIF) Century Therapeutics, Inc. (ALCD.) Century Therapeutics, Inc. (OMNN) Century Therapeutics, Inc. (CGPI.) Century Therapeutics, Inc. (CATX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 15673T100 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/13/26 Share - Related Items Shares Outstanding: 180.35 Most Recent Split Date: (:1) Beta: 1.55 Market Capitalization: $407.60 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.10 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.44 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/13/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.54 Price/Cash Flow: 169.92 Price / Sales: 3.55 EPS Growth vs. Year Ago Period: -112.36% vs. Previous Quarter: 56.00% Sales Growth vs. Year Ago Period: 12,667.72% vs. Previous Quarter: 2,515.96% ROE 03/31/26 - -49.89 12/31/25 - -1.43 09/30/25 - -10.01 ROA 03/31/26 - -37.42 12/31/25 - -1.05 09/30/25 - -6.58 Current Ratio 03/31/26 - 10.25 12/31/25 - 5.97 09/30/25 - 6.25 Quick Ratio 03/31/26 - 10.25 12/31/25 - 5.97 09/30/25 - 6.25 Operating Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Net Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Pre-Tax Margin 03/31/26 - - 12/31/25 - -8.84 09/30/25 - -21.79 Book Value 03/31/26 - 1.47 12/31/25 - 1.82 09/30/25 - 2.04 Inventory Turnover 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Equity 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00 Debt-to-Capital 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00

Powered by Zacks Investment Research ©